Recent theoretical and experimental studies highlight the possibility of new fundamental particle physics beyond the Standard Model that can be probed by sub-eV energy experiments. The OSQAR photon ...regeneration experiment looks for “Light Shining through a Wall” from the quantum oscillation of optical photons into “Weakly Interacting Sub-eV Particles”, like axion or axion-like particles (ALPs), in a 9 T transverse magnetic field over the unprecedented length of
2
×
14.3
m. No excess of events has been detected over the background. The di-photon couplings of possible new light scalar and pseudo-scalar particles can be constrained in the massless limit to be less than
8.0
×
10
-
8
GeV
-
1
. These results are very close to the most stringent laboratory constraints obtained for the coupling of ALPs to two photons. Plans for further improving the sensitivity of the OSQAR experiment are presented.
After pioneering gaseous detectors of single photon for RICH applications using CsI solid state photocathodes in MWPCs within the RD26 collaboration and by the constructions for the RICH detector of ...the COMPASS experiment at CERN SPS, in 2016 we have upgraded COMPASS RICH by novel gaseous photon detectors based on MPGD technology. Four novel photon detectors, covering a total active area of 1.5m2 have been installed in order to cope with the challenging efficiency and stability requirements of the COMPASS physics programme. They are the first application in an experiment of MPGD-based single photon detectors. All aspects of the upgrade are presented, including engineering, mass production, quality assessment and performance.
Perspectives for further developments in the field of gaseous single photon detectors are also presented.
Cholera was introduced into Haiti in 2010. Since then, more than 820 000 cases and nearly 10 000 deaths have been reported. Oral cholera vaccine (OCV) is safe and effective, but has not been seen as ...a primary tool for cholera elimination due to a limited period of protection and constrained supplies. Regionally, epidemic cholera is contained to the island of Hispaniola, and the lowest numbers of cases since the epidemic began were reported in 2019. Hence, Haiti may represent a unique opportunity to eliminate cholera with OCV.
In this modelling study, we assessed the probability of elimination, time to elimination, and percentage of cases averted with OCV campaign scenarios in Haiti through simulations from four modelling teams. For a 10-year period from January 19, 2019, to Jan 13, 2029, we compared a no vaccination scenario with five OCV campaign scenarios that differed in geographical scope, coverage, and rollout duration. Teams used weekly department-level reports of suspected cholera cases from the Haiti Ministry of Public Health and Population to calibrate the models and used common vaccine-related assumptions, but other model features were determined independently.
Among campaigns with the same vaccination coverage (70% fully vaccinated), the median probability of elimination after 5 years was 0-18% for no vaccination, 0-33% for 2-year campaigns focused in the two departments with the highest historical incidence, 0-72% for three-department campaigns, and 35-100% for nationwide campaigns. Two-department campaigns averted a median of 12-58% of infections, three-department campaigns averted 29-80% of infections, and national campaigns averted 58-95% of infections. Extending the national campaign to a 5-year rollout (compared to a 2-year rollout), reduced the probability of elimination to 0-95% and the proportion of cases averted to 37-86%.
Models suggest that the probability of achieving zero transmission of Vibrio cholerae in Haiti with current methods of control is low, and that bolder action is needed to promote elimination of cholera from the region. Large-scale cholera vaccination campaigns in Haiti would offer the opportunity to synchronise nationwide immunity, providing near-term population protection while improvements to water and sanitation promote long-term cholera elimination.
Bill & Melinda Gates Foundation, Global Good Fund, Institute for Disease Modeling, Swiss National Science Foundation, and US National Institutes of Health.
This study evaluates the prognostic performance of a 15 gene expression profiling (GEP) assay that assigns primary posterior uveal melanomas to prognostic subgroups: class 1 (low metastatic risk) and ...class 2 (high metastatic risk).
Prospective, multicenter study.
A total of 459 patients with posterior uveal melanoma were enrolled from 12 independent centers.
Tumors were classified by GEP as class 1 or class 2. The first 260 samples were also analyzed for chromosome 3 status using a single nucleotide polymorphism assay. Net reclassification improvement analysis was performed to compare the prognostic accuracy of GEP with the 7th edition clinical Tumor-Node-Metastasis (TNM) classification and chromosome 3 status.
Patients were managed for their primary tumor and monitored for metastasis.
The GEP assay successfully classified 446 of 459 cases (97.2%). The GEP was class 1 in 276 cases (61.9%) and class 2 in 170 cases (38.1%). Median follow-up was 17.4 months (mean, 18.0 months). Metastasis was detected in 3 class 1 cases (1.1%) and 44 class 2 cases (25.9%) (log-rank test, P<10(-14)). Although there was an association between GEP class 2 and monosomy 3 (Fisher exact test, P<0.0001), 54 of 260 tumors (20.8%) were discordant for GEP and chromosome 3 status, among which GEP demonstrated superior prognostic accuracy (log-rank test, P = 0.0001). By using multivariate Cox modeling, GEP class had a stronger independent association with metastasis than any other prognostic factor (P<0.0001). Chromosome 3 status did not contribute additional prognostic information that was independent of GEP (P = 0.2). At 3 years follow-up, the net reclassification improvement of GEP over TNM classification was 0.43 (P = 0.001) and 0.38 (P = 0.004) over chromosome 3 status.
The GEP assay had a high technical success rate and was the most accurate prognostic marker among all of the factors analyzed. The GEP provided a highly significant improvement in prognostic accuracy over clinical TNM classification and chromosome 3 status. Chromosome 3 status did not provide prognostic information that was independent of GEP.
New results for the double spin asymmetry A(1)(p) and the proton longitudinal spin structure function g(1)(p) are presented. They were obtained by the COMPASS Collaboration using polarised 200 GeV ...muons scattered off a longitudinally polarised NH3 target. The data were collected in 2011 and complement those recorded in 2007 at 160 GeV, in particular at lower values of x. They improve the statistical precision of g(1)(p)(x) by about a factor of two in the region x less than or similar to 0.02. A next-to-leading order QCD fit to the g(1) world data is performed. It leads to a new determination of the quark spin contribution to the nucleon spin, Delta Sigma, ranging from 0.26 to 0.36, and to a re-evaluation of the first moment of g(1)(p). The uncertainty of Delta Sigma is mostly due to the large uncertainty in the present determinations of the gluon helicity distribution. A new evaluation of the Bjorken sum rule based on the COMPASS results for the non-singlet structure function g(1)(NS) (x, Q(2)) yields as ratio of the axial and vector coupling constants vertical bar gA/gV vertical bar = 1.22 +/- 0.05 (stat.) +/- 0.10 (syst.), which validates the sum rule to an accuracy of about 9%.
PDF
